(MENAFN- EIN Presswire)
RNA Interference Drug Delivery Market
Looking forward, IMARC Group expects the global RNA interference (RNAi) drug delivery market to grow at a CAGR of 22.8% during 2021-2026.
SHERIDAN, WYOMING, UNITED STATES, October 19, 2021 /EINPresswire.com / -- According to IMARC Group's latest report, titled“RNA Interference (RNAi) Drug Delivery Market : Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the global RNA interference (RNAi) drug delivery market exhibited strong growth during 2015-2020. RNA interference (RNAi) drug delivery is a fundamental cellular mechanism that studies gene functions in eukaryotic organisms. It is also essential for silencing gene expressions for the development of new drugs. RNAi is considered a potential approach for treating various pathologic conditions, including cardiovascular diseases (CVDs), viral infections and cancer. It includes nonviral delivery of siRNA and viral delivery of shRNA that is used across various preclinical models and molecular targets for its transformational effect on modern medicine.
Request for a PDF sample of this report:
The global RNA interference (RNAi) drug delivery market is primarily driven by the increasing number of academic research institutes performing RNA therapeutic studies. The rising prevalence of chronic diseases, such as cardiac defects and cancer, is also propelling the growth of the market. In recent years, the demand for RNAi has escalated due to its high level of specificity, minor side effects, and ease of synthesis. Besides this, siRNA or microRNAs (miRNA) helps in developing personalized medicines and identifying altered cellular molecules and metabolites. Furthermore, advancements in the field of nanotechnology that facilitate nanoparticle drug delivery and the overall improvements in the healthcare infrastructure are expected to provide a positive impact on the market. Looking forward, IMARC Group expects the global RNA interference (RNAi) drug delivery market to grow at a CAGR of 22.8% during 2021-2026.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviors of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Competitive Landscape with Key Players:
Alnylam Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
Dicerna Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
Silence Therapeutics Plc
Breakup by Application:
Breakup by Technology:
Nanoparticle Drug Delivery
Pulmonary Drug Delivery
Nucleic Acid Drug Delivery
Aptamer Drug Delivery
Breakup by Region:
North America (United States, Canada)
Europe (Germany, France, United Kingdom, Italy, Spain, Others)
Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)
Ask Analyst for Customization and Explore full report with TOC & List of Figures:
We are updating our reports, If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.
Key highlights of the report:
Market Performance (2015-2020)
Market Outlook (2021-2026)
Market Drivers and Success Factors
The Impact of COVID-19 on the Global Market
Value Chain Analysis
Structure of the Global Market
Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
Related Reports by IMARC Group:
West Africa Generic Drug Market:
East Africa Generic Drug Market:
Europe Generic Drug Market:
India Minimally Invasive Surgery Market:
United States Minimally Invasive Surgery Market:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, and nanotechnology industries. We also provide cost model and manufacturing setup project reports through Syndicated Analytics, a subsidiary of IMARC Group.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
IMARC Services Private Limited
email us here
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.